Bristol Myers fronts new Schrödinger alliance with $55M upfront, expanding precision oncology profile
Bristol Myers Squibb has a new R&D partner, one to which they’re paying a pretty penny to use their discovery platform.
The pharma company is doling out $55 million upfront to Schrödinger $SDGR to work on up to five small molecules, with the potential for $2.7 billion in milestone payments. Schrödinger’s initial targets include HIF-2 alpha and SOS1/KRAS for a type of kidney cancer and KRAS-driven cancers, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.